spacer
home > ict > winter 2018 > a valued perspective
PUBLICATIONS
International Clinical Trials

A Valued Perspective

Acceleration of the integration of mobile health (mHealth) technologies into clinical trial operations is expected to be the catalyst for the adoption of disruptive research platforms with capabilities to overcome barriers in both clinically mature and emerging markets. While mHealth applications of smart devices, wearable biometric sensors, and telemedicine enable health monitoring, data collection, and patient communications have been around for some time. Despite this, their widespread use in clinical research should still be considered in its infancy. We continue to see the fast development of integrated mHealth platforms that have the potential to turn the traditional research model on its head – taking studies to patients rather than bringing patients into site-based studies. Powered by Big Data and connected across patients, researchers, and caregivers, emerging mHealth platforms will expand research participation, reduce costs, and integrate research with treatment in new models of personalised medicine based on real-world evidence.

The mHealth Disruption Four foundational trends are driving 21st century biomedical research:

  • Globalisation is expanding drug development into the emerging markets of Africa, Asia, and Latin America
  • Big Data is being harnessed to understand disease impacts at the population level and support evidence-based medical practice
  • Real-world evaluation is extending the continuum from traditional randomised clinical trials to new research models that assess real-world outcomes
  • Personalised medicine is advancing with targeted therapies tailored to smaller populations and the growth of patientcentric research

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Blackman has responsibility for aligning technology strategies and innovations with PPD’s evolving business needs. Within his role, David is responsible for creating and developing differentiating business capabilities together with partners and clients to accelerate clinical trial research. He has a strong passion for the design and implementation of mobile health and digital technologies solutions within clinical research. A graduate of the University of Johannesburg, South Africa, he combines more than 20 years of technological experience in development, process, and technology innovations with his commitment to implementing cutting-edge technologies as a platform to advance innovative technology solutions in clinical trials worldwide. He holds two patents and two patent applications for technology innovations.
spacer
David Blackman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization

February 1, Utrecht, The Netherlands ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with type 1 Diabetes, is pleased to announce the appointment of Leo Toole as Chief Financial Officer and provides a corporate update on its expansion pathway of Kaleido into key European markets in 2023.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement